Hugo Alarcan

Tours, 37032, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

Journal: Molecular neurobiology
Published: February 03, 2026

Exploration of Homocysteine Metabolism and Genetics in Autism Spectrum Disorder.

Exploration of Homocysteine Metabolism and Genetics in Autism Spectrum Disorder.

Journal: Nutrients
Published: October 27, 2025

Learning a distance for the clustering of patients with amyotrophic lateral sclerosis.

Learning a distance for the clustering of patients with amyotrophic lateral sclerosis.

Journal: BioData mining
Published: October 09, 2025

Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development.

Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development.

Journal: Journal of neuropathology and experimental neurology
Published: June 29, 2025

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

Journal: Fundamental & clinical pharmacology
Published: June 23, 2025

scFv intrabody targeting wildtype TDP-43 presents protective effects in a cellular model of TDP-43 proteinopathy.

scFv intrabody targeting wildtype TDP-43 presents protective effects in a cellular model of TDP-43 proteinopathy.

Journal: PloS one
Published: June 17, 2024

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.

Journal: Annals of the New York Academy of Sciences
Published: May 21, 2024

The effect of pH alterations on TDP-43 in a cellular model of amyotrophic lateral sclerosis.

The effect of pH alterations on TDP-43 in a cellular model of amyotrophic lateral sclerosis.

Journal: Biochemistry and biophysics reports
Published: December 11, 2023

Neutrophil to Lymphocyte Ratio as a Prognostic Marker in Amyotrophic Lateral Sclerosis.

Neutrophil to Lymphocyte Ratio as a Prognostic Marker in Amyotrophic Lateral Sclerosis.

Journal: Biomolecules
Published: September 28, 2023

Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients.

Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients.

Journal: International journal of molecular sciences
Published: June 12, 2023

Evaluation of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis.

Evaluation of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis.

Journal: European journal of neurology
Published: October 28, 2022

Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.

Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.

Journal: British journal of clinical pharmacology
Published: October 14, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026